“On Target” by ViZZZual.com is licensed under CC-BY-2.0
Last November, Tom Krohn announced that we would begin collaborating with Novartis and Pfizer to build a consistent framework for clinical trial eligibility criteria by developing target profiles and implementing them in our API. Our shared mission was to make it easier for people to find clinical trials that are right for them or their loved ones.
(Editor’s Note: In 2015, leadership of the LCOI-API was transitioned to TrialReach. You can learn more about their continuing work in innovation in clinical trial matching at TrialReach.com.)
Not long after that announcement, I was thrilled to be given the task of helping to lead such an important project. And, right now, I’m excited to share with you that some great strides have been made. In the last six months we’ve consulted with our partners from Pfizer and Novartis, along with other outside experts, to determine the best possibilities for presenting clinical trial eligibility criteria in a way that’s clear and consistent. From these discussions, we were able to form our first target profiles, which were made available to the public in late July through a major update to the LCOI-API. And, we’ve only just begun…
The Partnerships in Clinicals Trials conference brings together more than 1,300 industry specialists for four days of high-level idea exchange and innovation. It has been around for 23 years now, and in that time, the industry has seen a lot of positive change; however, much more is needed.
This year, I had the opportunity to serve on the conference’s advisory panel, and I look forward to seeing how many presentations and workshops will be focused on new approaches and true innovation.
Here are just of few potential highlights:
Susan Poteat presents during the PACCR workshop. (Photo by Gilles Frydman)
A few weeks ago, we had the privilege of hosting a group of ePatients, advocates and engaged industry professionals for our first Patients at the Center of Clinical Trials Workshop (PACCR). A number of Eli Lilly and Company’s drug development leaders joined the workshop to listen, learn, share initiatives and generate ideas focused on how the patient/participant experiences clinical trials and how that experience can be improved.
Though the workshop was somewhat small—30 to 40 people were present throughout the day—there was a great deal of wisdom and inspiration gained from the mashup of diverse experience and perspectives.
“I would like for researchers to define a minimum amount of information that all participants in all clinical trials will get, and for that minimum to be consistent across all organizations.”
–Lane Rasberry, Clinical Trial Participant and Wikipedian
On November 12, along with representatives from Novartis and Pfizer,I announced a collaboration at the Data to Knowledge to Action: Building New Partnerships technology conference in Washington, D.C. Our objective as a group is to build a consistent framework for clinical trial information to make it easier for patients and their families to find clinical trials that might be right for them.
By collaborating in this pre-competitive space, we hope to enable patient communities and patient-centric software companies to develop applications that help people match themselves with a study’s target profile across a variety of patient populations. We also hope to not only serve individuals looking for clinical trials, but to enroll trials faster and more efficiently—ultimately speeding drug development.